Adjuvant Osimertinib as a Standard Therapy for EGFR-Positive NSCLC
Treatment with osimertinib (Tagrisso) after surgery significantly reduced the risk of death…
Browsing Tag
EGFRPositive
New Standard in Operable EGFR-Positive Lung Cancer
CHICAGO -- Newly unveiled survival data should put an end to the debate on whether to treat operable EGFR-positive…
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study…
The recommended phase 2 dose was determined at 480 mgAFM24 has demonstrated a well-managed safety profilePharmacodynamic activity was observed at doses of 160 mg and higherThe maximum…
Clinical Challenge: Finding the Right Regimen in EGFR-Positive NSCLC
The phase III PACIFIC trial was a game-changer for patients with unresectable stage III non-small cell lung cancer (NSCLC) without…